Last reviewed · How we verify

NCT03047694: SemantiMATT

A Lexico-semantic Program on Tactile Tablet for Patients With Alzheimer's Disease

Terminated NA Last updated 24 April 2023
What this trial tests

NA trial testing tablet therapy in Alzheimer Disease in 1 participant. Terminated before completion.

Timeline
15 July 2019
Primary endpoint
15 January 2021
15 January 2021

Quick facts

Lead sponsorAssistance Publique - Hôpitaux de Paris
PhaseNA
StatusTerminated
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingsingle
Primary purposetreatment
Enrollment1
Start date15 July 2019
Primary completion15 January 2021
Estimated completion15 January 2021
Sites2 locations across France

Drugs / interventions tested

Conditions studied

Sponsor

Assistance Publique - Hôpitaux de Paris — full company profile →

Who can join

18 and older, any sex, with Alzheimer Disease. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Lexical semantic disorders are described in Alzheimer's disease, and their incidence in everyday life is important to the extent that these disorders affect expression and comprehension. Providing a tactile tablet stimulation, independent and complementary to speech therapy, could help to maintain certain abilities and reinforce the feeling of autonomy of the patients.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Alzheimer Disease

Currently open trials in the same condition.

Other Assistance Publique - Hôpitaux de Paris trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03047694.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing